NEW YORK–(BUSINESS WIRE)–
The following statement is being issued by Levi & Korsinsky, LLP:
TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF SALIX PHARMACEUTICALS, LTD. (SLXP) (“Salix” or “the Company”) PRIOR TO FEBRUARY 23, 2015 AND CONTINUE TO HOLD SUCH SHARES.
YOU ARE HEREBY NOTIFIED that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Salix to Valeant Pharmaceuticals International. Click here to learn more about the investigation: http://zlk.9nl.com/salix. There is no cost or obligation to you.
The Board of Directors of Salix agreed to sell the Company to Valeant Pharmaceuticals. Under the terms of the transaction, Salix shareholders will receive $158.00 in cash for each Salix common share they own. The investigation concerns whether the Board of Salix breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Valeant Pharmaceuticals International is underpaying for Salix shares.
If you own Salix common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/salix.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
- Health Care Industry
- Investment & Company Information
- Valeant Pharmaceuticals
Source Article from http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-150200233.html